Department of Molecular Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ashanti Region, Ghana.
Department of Medical Laboratory Science, University of Energy and Natural Resources, Sunyani, Ghana.
Immun Inflamm Dis. 2023 Aug;11(8):e976. doi: 10.1002/iid3.976.
BACKGROUND: T cell receptors play important roles in the development and progression of rheumatoid arthritis (RA). Their involvement has been reported in inflammatory autoimmune diseases. However, their role in predicting RA is still under exploration. This study evaluated the expression of CD183 (CXCR3) receptors on T-cells and other relevant biomarkers for detecting RA and determine their relationship with disease activity. METHODS: This unmatched case-control study included 48 newly diagnosed RA patients and 30 apparent healthy controls from the orthopedic units of Komfo Anokye Teaching Hospital (KATH), Kumasi and Korle-Bu Teaching Hospital (KBTH), Accra, Ghana. Sociodemographic data was obtained, and blood samples were also collected and processed for flow cytometric analysis. Statistical analyses were done using SPSS version 26.0 and R programming language. p < .05 was considered statistically significant. RESULTS: This study found a significant difference in age group (p < .0001), marital status (p = .0210), occupation (p = .0140), educational level (p = .0210) and religion (p = .0100) between RA patients and healthy controls. Moreover, hemoglobin level (p = .0010), waist circumference (p < .0001) and hip circumference (p = .0040) were significantly different between RA patients and controls. RA patients had significantly lower levels of CD4 CD183 compared with the control group (p < .001), and was positively correlated with DAS score (r = .0397, p = .789). In Receiver Operator Characteristics analysis, CD4 CD183 could significantly detect RA with a high area under the curve (AUC = 0.687, p = .018). At a cut-off of 0.082, CD4 CD183 was the best receptor biomarker for detecting RA with a sensitivity of 90.0%, specificity of 25.9%, a positive predictive value of 69.2%, and a negative predictive value of 58.3%. CONCLUSION: CD4 CD183 best predict RA and is positively correlated with disease activity. CD4 CD183 could serve as diagnostics and disease-monitoring biomarker for RA; however, it demonstrates low specificity. Future studies should be directed on CD4 CD183 and other biomarkers to augment their diagnostics performances and routine management in RA.
背景：T 细胞受体在类风湿关节炎（RA）的发展和进展中发挥着重要作用。它们的参与已在炎症性自身免疫性疾病中得到报道。然而，它们在预测 RA 中的作用仍在探索之中。本研究评估了 T 细胞上 CD183（CXCR3）受体的表达以及其他用于检测 RA 的相关生物标志物，并确定它们与疾病活动度的关系。
方法：这是一项未配对的病例对照研究，纳入了来自加纳库马西 Komfo Anokye 教学医院（KATH）和阿克拉 Korle-Bu 教学医院（KBTH）骨科病房的 48 例新诊断的 RA 患者和 30 名健康对照者。收集了社会人口统计学数据，并采集了血液样本进行流式细胞术分析。使用 SPSS 版本 26.0 和 R 编程语言进行统计分析。p<.05 被认为具有统计学意义。
结果：本研究发现 RA 患者与健康对照组在年龄组（p<.0001）、婚姻状况（p=.0210）、职业（p=.0140）、教育程度（p=.0210）和宗教信仰（p=.0100）方面存在显著差异。此外，血红蛋白水平（p=.0010）、腰围（p<.0001）和臀围（p=.0040）在 RA 患者和对照组之间也存在显著差异。RA 患者的 CD4 CD183 水平明显低于对照组（p<.001），且与 DAS 评分呈正相关（r=.0397，p=.789）。在接受者操作特征分析中，CD4 CD183 可以显著检测 RA，曲线下面积（AUC）较高（AUC=0.687，p=.018）。在截断值为 0.082 时，CD4 CD183 是检测 RA 的最佳受体生物标志物，其敏感性为 90.0%，特异性为 25.9%，阳性预测值为 69.2%，阴性预测值为 58.3%。
结论：CD4 CD183 可以最好地预测 RA，并且与疾病活动度呈正相关。CD4 CD183 可以作为 RA 的诊断和疾病监测生物标志物；然而，其特异性较低。未来的研究应针对 CD4 CD183 和其他生物标志物，以提高其诊断性能，并在 RA 的常规管理中加以应用。
Beijing Da Xue Xue Bao Yi Xue Ban. 2016-12-18
Int J Rheum Dis. 2013-6-10
Beijing Da Xue Xue Bao Yi Xue Ban. 2016-12-18
Ageing Res Rev. 2023-6
Inflammopharmacology. 2022-10
Inflammopharmacology. 2022-6
Front Immunol. 2021
Int J Mol Sci. 2021-3-18
Clin Ter. 2019
Zotero 插件
